Introduction
Cancer is the second most frequent cause of death worldwide, killing more than 8 million people every year and responsible for 1 in 7 deaths 1 . Globally, cancer deaths will increase by more than 50% over the coming decades, attributable to a number of driving forces: an ageing population in high income countries; increased exposure to carcinogens such as tobacco 2 , air pollution and asbestos 3 in low-and middle-income countries; declining physical activity with concomitant rise in obesity worldwide; and the continued expansion of the human population. While prevention and treatment of competing causes of mortality, such as cardiovascular disease and infections, have led to major improvements in life expectancy, the gains for cancer mortality have been more modest. For many patients, surgery remains the only curative option, but once the tumour has spread from its original site, cure is often elusive.
Nonetheless, in the last 20 years, our deepening understanding of the biology of cancer has enabled development of new therapeutics effective in a handful of cancers 4, 5 -it is this success that motivates the desire to systematically characterise cancer biology across all tumour types.
'Cancer' is a catch-all term used to denote a set of diseases characterised by autonomous expansion and spread of a somatic clone. To achieve this behavior, the cancer clone must modify multiple cellular pathways that enable it to disregard the normal constraints on cell growth, to modify the local microenvironment favoring its own proliferation, to invade through tissue barriers, to spread to other organs, and to evade immune surveillance 6 . No single cellular programme directs these behaviors.
Rather there are many different potential abnormalities from which individual cancers draw their own combinations. In that sense, the commonalities of macroscopic features across tumours belie a vastly heterogeneous landscape of cellular abnormalities.
This heterogeneity arises from the fundamentally stochastic nature of Darwinian evolution; a process that operates in somatic cells as much as species. The preconditions for Darwinian evolution are three: characteristics must vary within a population; this variation must be heritable from parent to offspring; and there must be competition for survival within the population. In the context of somatic cells, heritable variation arises from mutations acquired stochastically throughout life, notwithstanding potential additional contributions from heritable epigenetic variation. A subset of these mutations drive alterations in cellular phenotype, and a small subset of those variants confer an advantage on the clone in its competition to escape the tight physiological controls wired into somatic cells. The mutations conferring selective advantage on the clone we call 'driver mutations,' as opposed to the selectively neutral, or possibly slightly deleterious, 'passenger mutations. ' The discovery that cancers carry recurrent and specific genetic abnormalities in the 1970s 7 and early 1980s 8, 9 has fuelled four decades of research to define the catalogue of genes and mutations that can drive cancer. This has been accelerated by technological advances in genomic analysis, from gross descriptions of chromosome structure by chromosomal banding 7 and other cytogenetic techniques, through positional cloning of inherited cancer genes 10 , low-throughput capillary sequencing 11 and comparative genomic hybridisation 12 , to the current era of massively parallel whole genome sequencing [13] [14] [15] [16] [17] . The ever more populous catalogue of cancer genes has opened new therapeutic opportunities, with effective drugs being developed for the BCR-ABL fusion gene of chronic myeloid leukaemia, ERBB2 amplifications of breast cancer and the BRAF point mutations of melanoma [18] [19] [20] , amongst others.
International collaborations to sequence whole cancer genomes
The advent of massively parallel sequencing promised a future in which the cancer genome was finite and knowable. Early studies showed it was in theory feasible to document every somatic point mutation in a given cancer, every copy number change and every structural variant 14, 15 . In funding for ICGC projects has amounted to more than USD$900,000,000, with individual funding commitments in some countries being the largest biomedical grants they had ever awarded.
To date, there are 90 ICGC projects, of which 76 have submitted data across 21 primary organ sites and 31 distinct tumour types. At the time of writing, genomic data from 20,343 individual cancer patients were registered in the Data Coordination Center (https://dcc.icgc.org/), of whom 17,570 have molecular data, mostly exomes. Many major breakthroughs in the biology of individual tumour types have emerged from these studies, too numerous to cite exhaustively here, but including discoveries of new cancer genes and pathways [23] [24] [25] [26] [27] ; insights into the underlying mutational processes operative in human cancers [28] [29] [30] [31] [32] ; delineation of the patterns of tumour heterogeneity and clonal evolution [33] [34] [35] [36] ; and development of genomics approaches to inform cancer prevention 37 and clinical management of patients with cancer [38] [39] [40] . Many of these discoveries were enabled by novel computational and statistical methods designed to accurately detect various genomic alterations from sequencing data and analyse them across cohorts of patients to extract new biological insights.
The Pan-Cancer Analysis of Whole Genomes Collaboration
The early studies from ICGC and TCGA revealed both commonalities and differences of somatic genomic architecture across tumour types. Some cancer genes are mutated in many different tumour types; others are specific to a single histological subtype 41, 42 . All common tumour types are characterised by few frequently mutated genes and many rarely mutated genes; the patterns of co-mutation result in a huge diversity of combinations of driver mutations across individual patients [43] [44] [45] . Transcription factors and other proteins interact with enhancers, silencers, boundary elements, and overall chromatin structure to confer cell-specific regulatory responses, and recent studies have revealed the relevance of this interplay in cancer. [52] [53] [54] [55] [56] [57] Given that cells are pre-wired according to built-in control logics that involve coding and non-coding components, it stands to reason that changes in the DNA that affect these factors may underlie the tissue-specific nature of cancer onset and progression.
Indeed, some evidence points this way, for example there is evidence that epigenetic marks are associated with mutation densities in cancer, 58, 59 whereas cancer-risk associated germline variants typically occur in intergenic regions and show enrichment with enhancers. 60 The large number of samples subjected to whole genome sequencing by the ICGC now provides the opportunity to closely examine cancers beyond their protein-coding exomes, which are likely to provide only partial insights into the genomic landscape of cancer. Beyond providing insights into how mutations affect regulatory regions, whole genome sequencing can detail the full repertoire of classes of structural variation in cancers, facilitate resolving mutational processes and signatures acting in these, enable identifying viruses associated with cancers, and allow defining the full repertoire of germline variants in cancer patients. To tackle the various opportunties resulting from numerous cancer whole genome sequencing, 16 thematic Scientific Working Groups were formed and overseen by a Steering Committee for the PCAWG collaboration to pursue a multipronged analysis of the non-coding genome's influence on cancer (Table 1 ).
The maturing of datasets from individual ICGC and TCGA working groups presented the opportunity to formalise a meta-analysis of whole cancer genomes. However, algorithms for calling somatic mutations were not standardised among the different groups and had evolved considerably in the first few years of the consortium. For cross-tumour comparisons to be meaningful, the core bioinformatic analyses would need to be repeated using gold-standard, benchmarked, version-controlled algorithms. To tumour. In addition to whole genome sequencing, roughly half of the donors had at least one tumour specimen that had been subjected to whole transcriptome analysis using RNA-sequencing, also centrally collected and re-analysed.
Ultimately, we collected genome data from a total set of 2,834 donors.
After an extensive quality assurance process (described below), the data from 176 donors were deemed unusable and were excluded, leaving 2,658 donors, including 2,605 primary tumours and 173 metastases or local Demographically, the cohort included 1469 males (55%) and 1189 females (45%), with a mean age of 56 years (median 60 years; range 1-90 years). By using population ancestry-differentiated single nucleotide polymorphisms (SNPs) derived from the germline calls, we were able to estimate the population ancestry of each donor. The continental ancestry distribution was heavily weighted towards Europeans (77% of total) followed by East Asians (16%), as expected by large contributions from European, North American, and Australian projects (Supplementary Table 1 ).
Histopathology harmonisation
In order to simplify the process of cross-tumour analyses, the PCAWG specimens, were excluded from tumour-type specific cohort analyses due to lack of statistical power, but were included in pan-cancer analyses.
Uniform processing and variant calling
In order to generate a consistent callset that could be used for crosstumour type analysis, we analysed all samples using a uniform set of algorithms for alignment, variant calling, and quality control. We used the BWA-Mem algorithm 61 to align each tumour and normal sample to human reference build hs37d50.
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Somatic mutations were identified in the aligned data using three established pipelines, run independently on each tumour/normal pair. Each of the three pipelines, labeled "Sanger", "EMBL/DKFZ" and "Broad" after the computational biology groups that created and/or assembled them, consisted of multiple software packages for calling somatic single nucleotide variations (SNVs) and indels, copy number alterations (CNAs), and somatic structural variations (SVs). Each pipeline provided post-processing filters to remove likely false positive variant calls. A final set of filters were also run systematically across the entire set of PCAWG variants.
To assess the quality of the results from these three core pipelines, and to determine whether any other variant calling approaches would add additional value to the call set, we performed a systematic test and laboratory-based validation of 16 different computational pipelines. After this assessment, described below, we decided to run two additional callers 63, 64 on all samples to improve our ability to detect low-frequency SNVs and indels.
Following execution of each variant-calling pipeline, we merged the pipeline outputs for each variant type separately (SNVs, indels, CNAs, SVs) in order to achieve greater accuracy than provided by individual pipelines.
The SNV and indel merge algorithms were designed and tested using the laboratory validation exercise described below as a gold standard.
RNA-Sequencing data were uniformly processed to produce normalised gene-level expression values, splice variant quantifications and measurements of alternative promoter usage, and to identify fusion transcripts, quantify allele-specific expression, and identify RNA edit sites.
Calls of common and rare germline variants including single nucleotide variants, indels, SVs and mobile element insertions were generated using previously established principles for population-scale genetic polymorphism detection.
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The uniform germline data processing workflow comprised variant discovery using six different variant callers, followed by call-set merging, variant genotyping and statistical haplotypeblock phasing. Somatic retrotransposition events, including Alu and LINE/L1 insertions, 67 L1-mediated transductions 68 and pseudogene formation, 69 were called using a single, well-validated pipeline. 63 We removed these retrotransposition events from the SV call-set.
Mitochondrial DNA mutations were called using a published algorithm.
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Core alignment and variant calling by cloud computing
The requirement to uniformly realign and call variants on more than 6,800 whole genomes presented significant computational challenges. 
Quality assessment and control
Each donor and specimen was subject to a series of quality assessment Among the non-excluded specimens, 735 showed signs of oxidative damage, as evidenced by high levels of G>T transversions among the variant calls. 73 These artefactual variants were identified and removed by a purpose-built filter. 74 The 75 donors that were deemed to be borderline following QA were flagged for a variety of reasons including an unexpectedly high fraction (>15%) of paired reads mapping to different chromosomes, an unusual mutational signature that did not correspond to a known biological process or artefact, or a level of tumour-in-normal contamination that approached, but did not exceed, the cut-off level (15%). We consider these suitable for some, but not all, analytic questions and left the choice of whether to use them or not to the downstream analytic groups.
Validation, benchmarking and merging
In order to evaluate the performance of each of the mutation-calling pipelines and determine the strategy for integrating them, we performed a large-scale deep sequencing validation experiment. We selected a pilot set of 63 tumour/normal pairs from 23 cancer types across 26 contributing sequencing projects, on which we ran the three main mutation calling pipelines, and an additional 13 tools. The 63 tumours were chosen to have a wide range of somatic mutation frequencies in order to provide accurate representation of sensitivity and specificity estimates across samples. Of the 63 cases, 50 had sufficient DNA in both tumour and normal samples to enable deep sequencing targeting the putative mutated sites through DNA hybridisation capture. We selected ~250,000 SNVs and indels for validation by first stratifying mutations based on the number of methods that called them and then evenly sampling from each of these strata. This enabled us to estimate, for each method, false-positive and false-negative rates, which were used to calculate performance metrics such as precision, sensitivity and a combined (F1) score.
Next, we examined multiple methods for integrating calls made by each of the three pipelines. We evaluated the performance of simple methods (such as taking the union or intersection of the calls) as well as more sophisticated methods that used, beyond the three pipelines, additional parameters (such as coverage, variant allele frequency and nearby sequence context) to predict whether a mutation is real or not. The final consensus calls for SNVs were based on a simple approach that required two or more methods to agree on a call. For indels, because methods were less concordant, we used logistic regression to integrate the calls. The SV merge accepted all calls made by two or more of the four primary SV callers (one pipeline has two SV callers).
Overall, the sensitivity and precision of the consensus calls were 95%
(CI 90% : 88-98%) and 95% (71-99%) respectively for SNVs. For indels, in keeping with greater challenges in identification accuracy, sensitivity and precision were 60% (34-72%) and 91% (73-96%). Using manual assessment of called SVs as a gold standard, the false discovery rate of merged calls was estimated to be 2.5%, with 10% of true calls rejected.
For all mutation types, accuracy was reduced in repeat-rich regions relative to coding and other unique regions. ; Figure 3 ). Other factors are also likely to contribute to the correlations among classes of somatic mutation, since there is evidence that some DNA repair defects can cause multiple types of somatic mutation 75 and a single carcinogen can cause a range of DNA lesions. 
Pan-cancer burden of somatic mutations
